Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.97 |
| ▸ | HPGD | P15428 | 4/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | GLA | P06280 | 1/20 | 0.97 |
| ▸ | GAA | P10253 | 1/20 | 0.97 |
| ▸ | CASP1 | P29466 | 1/20 | 0.97 |
| ▸ | CASP7 | P55210 | 1/20 | 0.97 |
| ▸ | MAOA | P21397 | 1/20 | 0.91 |
| ▸ | MAOB | P27338 | 2/20 | 0.62 |
| ▸ | STS | P08842 | 11/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625077 | 1.00 | CYP1A2 (1.00) | CYP1A2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL30465069 | 0.98 | KDM4E (1.00) | CYP1A2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL3768560 | 0.98 | KDM4E (1.00) | CYP1A2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL3757463 | 0.95 | MAOA (1.00) | CYP1A2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL10791718 | 0.87 | CYP1A2 (0.77) | CYP1A2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL10793789 | 0.85 | ALDH1A1 (0.77) | CYP1A2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL10795665 | 0.82 | KDM4E (0.70) | CYP1A2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL10790036 | 0.82 | KDM4E (0.70) | CYP1A2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL10789263 | 0.82 | MAOA (0.77) | CYP1A2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL9336449 | 0.81 | KDM4E (0.71) | CYP1A2ALDH1A1HPGDHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846965-B2 | a non-steroidal sulphamate compound such as 6-Oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulphamate, suitable for use as an inhibitor of estrone sulphatase, for the treatment of endocrine-dependent cancers and tumors, such as the breast and endometrium | STERIX LIMITED (GB) | 2010-12-07 | — | — | US | disclosed |
| US-20070173531-A1 | Compound | REED MICHAEL J | 2007-07-26 | — | — | US | disclosed |
| US-7202272-B2 | Compound | STERIX, LTD. (GB) | 2007-04-10 | — | — | US | disclosed |
| US-6921776-B1 | Compound | STERIX LIMITED (GB) | 2005-07-26 | — | — | US | disclosed |
| US-20050154050-A1 | Compound | REED MICHAEL J (GB) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173531-A1 | Compound | HSD17B11, NR5A1, CYP17A1 | CYP1A2 91/4885ALDH1A1 611/4885HPGD 260/4885 |
| US-20050154050-A1 | Compound | HSD17B11, NR5A1, CYP17A1 | CYP1A2 91/4885ALDH1A1 611/4885HPGD 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.